1,720,967 research outputs found
Cytokeratin positivity in bone marrow cells as predictor of onset of bone metastases in patients with advanced breast cancer.
No full textObjective: Despite screening programs, advances in therapeutic approaches and understanding the molecular bases of cancer biology, breast cancer (BC) remains the first cause of cancer death in women aged over 50 years. Bone is one of the most common sites of metastasis in BC patients, and the presence of disseminated tumor cells in bone marrow (BM) seems to have a strong independent prognostic value. The aim of this study was to investigate whether the immunocytochemical detection
of disseminated tumor cells in BM can be considered as predictor of onset of bone metastases in patients with advancer BC.
Material and Methods: A group of 21 surgically treated women (median age 54, range 47–68 years) with advanced (stage II-III) BC and no evidence of distant metastases at first diagnosis were followed-up for at least 24 months. All patients underwent whole bone scan or 18 F-FDG-PET for inclusion in the study, together with a baseline BM aspirate from the posterior iliac crest. The cells were stained with a monoclonal antibody against cytokeratin (CK). A according to the ISHAGE guidelines, CK+cells were scored as tumor cells. Six out of 21 (28.6 %) patients (cases) developed bone metastases, while 15 (controls) had no evidence of distant metastases.
Results: Risk ratio (RR), 95 % confidence interval (CI), and the relative p-value (p) using Fisher exact test between cases and controls were calculated. The following parameters have been considered: age 5 AN+)(RR=2.5, 95 %CI 0.91-6.87, p=0.11), and
CK+(RR=3.21, 95 %CI 1.25-7.78, p=0.02).
Conclusion: The presence of CK+cells in the BM specimen should be considered a strong predictor (p5 AN+and ER- are weak predictors
Relationship between bone remodeling serum markers and BMD in premenopausal women with advanced breast cancer
No full textPostmenopausal women with osteoporosis and risk of breast cancer. A case-control study in a high-risk population
No full textLumbar-spine bone mineral density changes following chemotherapy in women with estrogen receptor-positive breast cancer and lymph node metastasis.
No full textTamoxifen only benefits patients with estrogen receptor-positive (ER+) breast cancer (BC), and those with lymph node involvement (pN+) also require adjuvant chemotherapy, which may cause ovarian failure leading to bone
loss. The aim of this preliminary study was to evaluate the changes of BMD after adjuvant chemotherapy in patients with BC.
Material and Methods: A group of 14 postmenopausal women (median age 55, range 49–59 years) with ER+, pN+, invasive ductal carcinoma, who had undergone curative surgery, were treated with tamoxifen (20 mg/day) and adjuvant CMF standard regimen. Using DXA (Hologic QDR 4500 C, Waltham, USA) the BMD (g/cm2) at the lumbar (L2-L4) spine (LS) was measured. The following serum biochemical parameters were also measured, before and after (12 months) the treatment: albumin, alkaline phosphatase (AP), blood urea nitrogen (BUN), calcium, cortisol (8 a.m.), osteocalcin, PTH, thyroid stimulating hormone (TSH), and 25-hydroxyvitamin D (25(OH)D). Student's t-test was used and a p-value<0.05 was considered significant.
Results: The baseline and post-chemotherapy main biochemical parameters and L-BMD were: albumin: 4.1±0.2 vs. 4.0±0.3 g/dL, p=0.31; AP: 161.2±53.1 vs. 207.0±56.3 U/L, p=0.03; BUN: 14.2±2.3 vs. 15.6±2.9 mg/dL, p=0.17; calcium: 2.4±0.2 vs. 2.3±0.2 mmol/L, p=0.19; cortisol: 526.9±118.6 vs. 579.4±102.1 nmol/L, p=0.22; osteocalcin: 9.7±7.1 vs. 10.6±8.3 ng/mL, p=0.76; PTH: 32.8±21.0 vs. 46.6±22.1 ng/L, p=0.10; TSH: 1.9±0.9 vs. 1.0±0.8 U/mL, p=0.10; 25(OH)D: 31.4±9.6 vs. 39.6±11.3 ng/mL, p=0.05; LS-BMD: 0.981±0.124 vs. 0.886±0.236, p=0.04.
Conclusion: In this group of patients with BC a significant reduction in LS-BMD values was observed, together with an increase in AP and 25(OH)D serum levels, while the other biochemical parameters did not change significantly.
This study confirms the negative effect of chemotherapy on bone in postmenopausal women, suggesting the need of prevent bone loss despite tamoxifen administration
Relationship between bone serum markers in patients with bone metastases from non-small cell lung carcinoma.
No full textInvasive breast cancer and risk factors of bone metastasis in women who underwent curative surgery. A retrospective case-control study.
No full textRelationship between bone turnover marker, bone density and serum estrogen levels in recently menopausal women
No full textOsteoporosis is the most common non-traumatic skeletal disorder, which weakens bone and increases the fracture risk. Hypoestrogenic status of menopause accelerate the age-related bone loss, leading to increased risk of osteoporosis development, but the responsibility of each variable in conditioning bone mass alteration is unclear. The aim of this study was to investigate the relationship between some bone turnover markers, such as alkaline
phosphatase (ALP), osteocalcin and PTH, BMD and circulating 17-β- estradiol (e2) in recently menopausal women.
Patients & Methods: A group of 21 postmenopausal women (median age 52 years, range 49–54 years) were enrolled in the study. All patients underwent lumbar spine (LS) BMD measurement by DXA. The coefficient of variation was <1 %. ALP, osteocalcin, PTH, and e2 serum levels were also measured. Patients with severe renal or hepatic impairment or major cardiovascular diseases were excluded from this study.
Results: The mean ALP, osteocalcin, PTH, and e2 serum levels were 141.1±13.8 U/L, 4.2±1.3 ng/mL, 67.1±1.3 ng/mL, and 99.7±15.8 pmol/L, respectively. As expected, an inverse correlation between age and both LS-BMD (R=0.50, p=0.021) and e2 (R=0.89, p=0.00001) was found. No correlation between ALP and age (R=0.40, p=0.06), e2 (R=0.35, p=0.12), LS-BMD (R=0.30, p=0.19), PTH (R=0.13, p=0.54) and osteocalcin (R=0.05, p=0.99). There was a weak inverse relationship between LS-BMD and osteocalcin (R=0.40, p=0.07), but a significant relationship between e2 and both BMD (R=0.52, p=0.014) and osteocalcin (R=0.0.46, p=0.038). At multivariate analysis, only age and e2 were independent predictors of LS-BMD changes.
Conclusion: Our study suggests that, in recently menopausal women, hormonal status as defined by e2 and partially by osteocalcin represents useful predictors of bone loss
Bone alkaline phosphatase and osteocalcin as markers of osteoporosis in postmenopausal women with breast cancer and bone metastases.
No full textObjective(s): Breast cancer (BC) is a heterogeneous tumor that occurs predominantly in elderly women. The overall estimated number of new BCs in the USA in 2011 was 232,000, accounting for about one-third of cases of cancer in women. It continues to be one of the most common causes of cancer death. BC frequently metastasizes to the skeleton, and it is estimated that 85% of individuals with advanced disease harbor bone metastases (BM). Bone alkaline phosphatase (BAP) and osteocalcin are widely used to check the response to therapy in patients with progressive bone disease. The aim of this study was to evaluate whether a correlation exists between bone remodeling serum markers BAP and osteocalcin, and BMD in women with BC and BMs.
Material & Methods: Data from a group of 18 postmenopausal women (median age 65 years, range 54-74 years) who have undergone surgery for invasive BC and successively developed BMs were retrospectively analyzed. Lumbar spine (L2-L4) BMD using DXA, and serum BAP and osteocalcin were measured in all patients. According to the WHO criteria, 13 patents (subgroup A) had mild or moderate osteoporosis (T-score -2.5 through -4 SD), while 5 (subgroup B) had severe osteoporosis (T-score of<-4 SD) Results: Age (62.2±5.6 vs. 68.8±4.2 years, p=0.061), baseline BAP (27.8±7.3 vs. 34.8±7.4 U/L, p=0.088) and osteocalcin (22.8±7.4 vs. 31.4±8.7 ng/mL, p=0.081) did
not differ significantly (subgroup A vs. B). There was no relationship between age, BMD, BAP and osteocalcin serum levels in subgroup B, while in the subgroup A, only a week correlation (R=0.72, p=0.018) between BAP and
osteocalcin was observed, and no relationship (p=NS) between BMD, age, and serum markers was found. Conclusion(s): In patients with BMs from advanced BC, the action of local osteolytic factors, such as PTHrP, together
with direct bone resorption by lytic metastasis, may cause a severe bone disease. In postmenopausal women with BC and BMs the effects on bone of age and cancer together likely overlap, and the relationship between age, BMD, and bone remodeling serum markers is not maintained.
References: Lumachi F et al. Anticancer Res 2009;29:1551
Automated protein-array chip system for bone turnover markers measurement in pre- and postmenopausal women with osteoporosis
No full text- …
